(Q42907028)

10 November 2017

title

Do We Know When and How to Lower Lipoprotein(a)? (English)

1 reference

10 November 2017

5

Szilard Voros

1 reference

10 November 2017

Eric Krivitsky

2

1 reference

10 November 2017

Zhen Qian

3

1 reference

10 November 2017

Gustavo Vazquez

4

1 reference

10 November 2017

Joseph Miller

6

1 reference

10 November 2017

Parag H. Joshi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20842562

13 July 2024

language of work or name

1 reference

1 August 2010

1 reference

full work available at URL

10 November 2017

http://link.springer.com/content/pdf/10.1007/s11936-010-0077-6.pdf

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1007/S11936-010-0077-6

http://link.springer.com/article/10.1007/s11936-010-0077-6/fulltext.html

13 July 2024

1 reference

https://api.crossref.org/works/10.1007/S11936-010-0077-6

http://link.springer.com/content/pdf/10.1007/s11936-010-0077-6

13 July 2024

1 reference

DOI

https://api.crossref.org/works/10.1007/S11936-010-0077-6

Current treatment options in cardiovascular medicine

13 July 2024

published in

1 reference

10 November 2017

volume

12

1 reference

10 November 2017

issue

4

1 reference

10 November 2017

page(s)

396-407

1 reference

Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial.

10 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11936-010-0077-6

Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-010-0077-6

Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-010-0077-6

Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance

21 January 2018

1 reference

12 December 2020

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

1 reference

12 December 2020

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

1 reference

12 December 2020

Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women

1 reference

12 December 2020

Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans

1 reference

12 December 2020

Cardiology patient pages. Prothrombin 20210 mutation (factor II mutation).

1 reference

12 December 2020

A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients

1 reference

12 December 2020

Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease

1 reference

12 December 2020

Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy

1 reference

12 December 2020

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group

1 reference

12 December 2020

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

1 reference

12 December 2020

The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial

1 reference

12 December 2020

Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice

1 reference

12 December 2020

Extended-release niacin or ezetimibe and carotid intima-media thickness.

1 reference

12 December 2020

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

12 December 2020

Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia

1 reference

12 December 2020

Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study

1 reference

12 December 2020

The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms.

1 reference

12 December 2020

Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study

1 reference

12 December 2020

Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces

1 reference

12 December 2020

Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription

1 reference

12 December 2020

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

1 reference

12 December 2020

Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases

1 reference

12 December 2020

Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins

1 reference

12 December 2020

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1

1 reference

12 December 2020

Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions

1 reference

12 December 2020

Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy

1 reference

12 December 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

12 December 2020

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

1 reference

12 December 2020

The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells

1 reference

12 December 2020

Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)

1 reference

12 December 2020

Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions

1 reference

12 December 2020

Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause

1 reference

12 December 2020

Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations

1 reference

12 December 2020

Genetic variants associated with Lp(a) lipoprotein level and coronary disease

1 reference

12 December 2020

Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random

1 reference

12 December 2020

Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease

1 reference

12 December 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

10 November 2017

1026029968

0 references

1 reference